Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.

@article{Meltzer1999PerspectiveAT,
  title={Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.},
  author={David O. Meltzer},
  journal={The Journal of clinical psychiatry},
  year={1999},
  volume={60 Suppl 3},
  pages={32-5; discussion 36-7}
}
A valid and compelling cost-effectiveness analysis of psychopharmacologic treatment of schizophrenia requires the application of analytically rigorous methods. All cost-effectiveness analyses must consider the issue of perspective as the well as the appropriate measurement of benefits and costs. Many of these issues are particularly difficult to address in the case of schizophrenia. Since costs may be borne by a wide range of parties, the choice of perspective is of critical importance. The… CONTINUE READING

From This Paper

Topics from this paper.
10 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…